Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trialBrian G. Feagan, Laurent Peyrin‐Biroulet, Ronald Fogel et al.|The Lancet|2021Cited by 452
Effects of filgotinib on semen parameters and sex hormones in male patients with inflammatory diseases: results from the phase 2, randomised, double-blind, placebo-controlled MANTA and MANTA-RAy studiesWalter Reinisch, Dirk Vanderschueren, Wayne J.G. Hellstrom et al.|Annals of the Rheumatic Diseases|2023Cited by 44
A15 EFFICACY AND SAFETY OF FILGOTINIB AS INDUCTION THERAPY FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDYB G Feagan, Laurent Peyrin‐Biroulet, Edward V. Loftus et al.|Journal of the Canadian Association of Gastroenterology|2021Cited by 8